What functional‑medicine treatment should be recommended for a post‑menopausal woman presenting with progressive frontotemporal hair loss, scalp erythema, and histologically confirmed scarring alopecia (frontal fibrosing alopecia)?

Treatment Approach for Frontal Fibrosing Alopecia

For a postmenopausal woman with frontal fibrosing alopecia (FFA), initiate combination therapy with oral dutasteride (0.5 mg daily) plus intralesional triamcinolone acetonide injections to the affected hairline, and if inflammation persists after 3-6 months, add hydroxychloroquine (200-400 mg daily). 1, 2, 3

Critical Distinction: FFA is NOT Female Pattern Hair Loss

The evidence provided primarily addresses female pattern hair loss (FPHL), which is a completely different condition from frontal fibrosing alopecia. FFA is a scarring (cicatricial) alopecia with lymphocytic inflammation and permanent follicular destruction 4, 5, 6. The treatments for FPHL (minoxidil, finasteride for pattern hair loss) have limited applicability here because:

• FFA involves irreversible follicular stem cell loss and fibrosis 3, 5
• The goal is disease stabilization, not regrowth, since scarring is permanent 2, 3
• FFA requires anti-inflammatory therapy, not just hair growth stimulants

Evidence-Based Treatment Algorithm

First-Line Therapy (Start Immediately)

Oral 5α-reductase inhibitor:

• Dutasteride 0.5 mg daily is preferred over finasteride based on the strongest evidence for FFA specifically 1, 2, 7
• In the Duke University series, dutasteride was most effective at halting disease progression in FFA patients 7
• 88% response rate (158/180 patients) across studies for 5α-reductase inhibitors 2

Plus intralesional corticosteroids:

• Triamcinolone acetonide 5-10 mg/mL injected into the advancing hairline every 4-6 weeks 2, 3, 8
• 88% response rate (181/204 patients) for intralesional steroids 2
• Target areas of active inflammation (perifollicular erythema) and the advancing edge

Second-Line Addition (If Progression Continues After 3-6 Months)

Hydroxychloroquine:

• 200-400 mg daily 1, 3
• Add when inflammation persists despite first-line therapy
• Has immunomodulatory effects relevant to the lymphocytic infiltrate in FFA 3

Adjunctive Considerations

Topical minoxidil 5%:

• May be added for any coexisting pattern hair loss or to support remaining follicles 9, 8
• Note: Minoxidil has shown efficacy in cicatricial alopecias including FFA, potentially through antifibrotic effects 9
• However, this is not the primary treatment for FFA

Topical corticosteroids:

• Can be used between intralesional injections for persistent scalp erythema 3, 8
• Less effective than intralesional route but may provide additional anti-inflammatory benefit

What NOT to Do

Avoid oral prednisone as monotherapy:

• Only temporarily delays rapid hair loss and is not sustainable long-term 2

Do not rely on topical treatments alone:

• FFA requires systemic therapy due to the depth of follicular inflammation 1

Do not delay treatment:

• Hair loss is permanent once scarring occurs 2, 3
• Early intervention is critical before irreversible follicular destruction

Monitoring and Expectations

Realistic goals:

• Treatment aims to halt progression, not restore lost hair 2, 3
• Assess response by measuring hairline position and monitoring for new perifollicular erythema every 3 months
• Stabilization of the hairline = treatment success

Duration:

• Continue therapy indefinitely as FFA may reactivate if treatment is stopped 8
• Some patients achieve spontaneous stabilization, but this is unpredictable

Key Pitfalls to Avoid

1. Misdiagnosing as FPHL: FFA has perifollicular erythema, follicular hyperkeratosis, and loss of follicular openings on examination—FPHL does not 4, 5

2. Waiting for "natural stabilization": While FFA may spontaneously stabilize, waiting risks permanent hair loss that could have been prevented 2

3. Monotherapy approach: The Spanish consensus emphasizes multimodal therapy from the start because hair loss is irreversible 1

4. Ignoring eyebrow involvement: 50% of FFA patients have eyebrow loss; these areas also require treatment 8, 5

Laboratory Assessment

Before initiating dutasteride, check:

• Baseline liver function (dutasteride is hepatically metabolized)
• Pregnancy status (teratogenic—though postmenopausal status makes this less relevant)
• Consider thyroid function, ANA to rule out other autoimmune conditions 4, 6

The evidence for vitamin D, iron, and zinc supplementation comes from FPHL studies and has no established role in FFA treatment 4.